Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
To evaluate the safety and tolerance of human CD19 targeted T Cells injection for the treatment of relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.
CD19-positive|Acute Lymphoblastic Leukemia
DRUG: Human CD19 targeted T Cells Injection
DLT, 28 days post infusion
Duration of CAR-positive T cells in circulation, 2 years post infusion|The concentration of CD19-positive B cells in peripheral blood., 2 years post infusion|Overall response rate (ORR) after administration, 90 days post infusion|Duration of remission (DOR) after administration, 2 years post infusion|Progress Free Survival (PFS) after administration, 2 years post infusion|Overall Survival (OS)after administration, 2 years post infusion|The immunogenicity of Human CD19 targeted T Cells Injection. (the detection of human anti-mouse antibody), 2 years post infusion
Participants with relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia can participate if all eligibility criteria are met. Tests required to determine eligibility include disease assessments, a physical exam, electrocardiograph and blood draws. Participants receive chemotherapy prior to the infusion of CD19 CAR+ T cells. After the infusion, participants will be followed for side effects and effect of CD19 CAR+ T cells. Study procedures may be performed while hospitalized.